Acumen Pharmaceuticals, Inc. has received a $3.6 million U01 grant from the National Institute of Aging (NIA) to fund the preclinical and early clinical development of ACU193, a humanized monoclonal antibody targeting amyloid beta oligomers for the treatment of Alzheimer’s disease (AD).

U01 grants, or Cooperative Agreement Awards, support research programs to be performed by principal investigators in cooperation with NIA personnel. Acumen aims to use this U01 award to conduct clinical grade manufacturing of ACU193 and preclinical toxicology studies required for an Investigational New Drug (IND) application to the U.S. Food and Drug Administration (FDA). After the IND goes into effect, Acumen will subsequently initiate first-in-human clinical testing in patients with AD.